Celldex Therapeutics (FRA:TCE2) Cyclically Adjusted PB Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:TCE2 Celldex Therapeutics Inc FRA:TCE2
56 GF Score
Price €33.44
GF Value €2.49
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Celldex Therapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Celldex Therapeutics  (FRA:TCE2) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Celldex Therapeutics Cyclically Adjusted PB Ratio Related Terms


Celldex Therapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Celldex Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celldex Therapeutics Cyclically Adjusted PB Ratio Chart

Celldex Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.43 1.75 1.79 1.35 1.63

Celldex Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.05 1.43 1.55 1.91 2.57

FRA:TCE2 vs IRON, NAMS, MBX: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Celldex Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celldex Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celldex Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Celldex Therapeutics's Cyclically Adjusted PB Ratio falls into.


FRA:TCE2
56GF Score
Celldex Therapeutics Inc FRA:TCE2
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celldex Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Celldex Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Celldex Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=7.962/333.9520*333.9520
=7.962

Current CPI (Jun. 2026) = 333.9520.

Celldex Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201609 28.619 241.428 39.587
201612 31.322 241.432 43.325
201703 27.991 243.801 38.341
201706 23.891 244.955 32.571
201709 21.048 246.819 28.478
201712 21.316 246.524 28.876
201803 11.407 249.554 15.265
201806 10.502 251.989 13.918
201809 9.816 252.439 12.986
201812 9.076 251.233 12.064
201903 7.814 254.202 10.265
201906 6.497 256.143 8.471
201909 5.847 256.759 7.605
201912 4.935 256.974 6.413
202003 4.302 258.115 5.566
202006 5.431 257.797 7.035
202009 4.957 260.280 6.360
202012 4.320 260.474 5.539
202103 4.170 264.877 5.257
202106 3.880 271.696 4.769
202109 8.075 274.310 9.831
202112 7.894 278.802 9.456
202203 7.653 287.504 8.889
202206 7.468 296.311 8.417
202209 7.487 296.808 8.424
202212 6.476 296.797 7.287
202303 5.898 301.836 6.526
202306 5.383 305.109 5.892
202309 4.930 307.789 5.349
202312 6.952 306.746 7.569
202403 11.781 312.332 12.596
202406 11.454 314.175 12.175
202409 10.614 315.301 11.242
202412 10.869 315.605 11.501
202503 9.803 319.799 10.237
202506 8.409 322.561 8.706
202509 7.664 324.800 7.880
202512 6.745 324.054 6.951
202603 5.948 330.213 6.015
202606 7.962 333.952 7.962

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Celldex Therapeutics (FRA:TCE2) Overvalued in 2026?

Based on GuruFocus' analysis, Celldex Therapeutics stock appears to be overvalued. The current stock price of €33.44 is trading 1243% above its estimated GF Value™ of €2.49. GuruFocus considers Celldex Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:TCE2:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €2.49 vs. price of €33.44 (1243% above fair value)
  • GF Score™: 56/100 with 6 warning signs

No single metric tells the full story. See the FRA:TCE2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Celldex Therapeutics Business Description

Other Exchanges CLDX:USA
Address 53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
56GF Score

Get the complete analysis for FRA:TCE2

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€33.44
Price
€2.49
GF Value